Ray's refill came back a different color the same week a TV show told him to worry about generic drugs.
By Justin Yamashita, MSc. Benchtop, site, CRO: three levels of basic and clinical research, explained without spin.
Four things most people don't know about generic drugs
A new pill color usually means a new maker, not a new medicine. Trademark law doesn't let a generic look exactly like the brand, and each maker picks its own shape and color.
Most generics must pass a clinical study before they're sold: volunteers' blood shows whether the copy lands in the body the same way as the brand. If it doesn't, it isn't approved.
"80% to 125%" doesn't mean a generic can have 20% less medicine. Across 2,070 studies the FDA reviewed, generics differed from the brand by about 3.5 to 4.5% on average.
The scary part of the story you may have seen on TV is real too. It lives in the factory, and it applies to brand name medicines as well.
Same recipe. The question is the kitchen.
Ray's Kitchen, Refill Day
Same prescription with a different looking pill. Nobody told him why.
Two weeks after Theo's checkup, Maya stops by her dad's place on her way home and finds him at the kitchen table with his pill bottle open and two tablets in his hand. One is small, round and white while the other is oval and pale yellow.
"They switched me," Ray says. "This is the new one. I watched a thing about generic drugs. Dirty factories overseas, eye drops that blinded people. I'm not putting this in my body."
Maya has the answer ready. Generics are fine, Dad, everybody takes them. She almost says it.
Sam the Skeptic and Rooty the Researcher are sitting in, as always.
Sam leans toward Rooty. "She would be right, though. Right?"
"Mostly," Rooty says. "But he's not entirely wrong either. That's what makes this one hard. Watch."
The Black Box Warning: The Bad Batch
One bad can is a real problem. It isn't the whole shelf.
Tactic: The Bad Batch.
Move 1. Lead with a real failure. The worse, the better.
Put it this way. One car model gets recalled for faulty brakes. That recall is real and it matters.
Move 2. Stretch it to cover everything with the same label.
Put it this way. Nobody concludes that every car on the road has bad brakes. They check whether theirs is on the recall list.
Move 3. Skip the question that would break it: which factory, which batch, and was mine one of them?
Put it this way. Look up your own car. Then look up your own pill.
She Checks Herself First
First, Maya checks herself. Is she here to get him to take the pill, or to help him feel sure about it? Those aren't the same conversation. And she has to make sure she double checks that her presumptions are correct as well.
Then she pictures his side. Nine years on the same little white pill, and now it looks different, nobody explained why, and the TV just gave him a reason to be scared. That isn't paranoia. That's a man noticing something changed.
She sits down at the corner of the table, next to him. "You're right that it's different. I'd want to know why too. What would make you feel okay about it?"
Ray turns the yellow pill over. "If somebody who actually knows told me it's the same medicine."
They Look Together
"Want to call the pharmacy and ask so we aren’t just working off what I think?" Maya says. She puts it on speaker so they can both hear.
The pharmacist pulls up his record. The pharmacy switched to a different company's version of the generic this month so it’s the same medicine, same strength, but a different maker, different shape and color. She reads him the letters and numbers stamped on the tablet so he can match it himself.
"Why didn't anybody tell me?" Ray asks.
"Fair question," the pharmacist says. "We buy from whichever company our supplier has that month, and the pill changes with it. We don't usually call ahead when that happens. If it bothers you, ask us to keep you on the same maker."
Maya writes that down too. It's the first time either of them has heard that the pharmacy, not the doctor, picks who makes the pill.
Rooty turns to Sam. "That's PAUSE. She asked the source, and they looked together."
"Did she win?"
"She didn't try to."
Know a Ray? Forward this with one line: "Saw this and thought of your pills changing color. The top part answers it in a minute."
What Ray Decides
Ray takes the Medication and Supplement Log off the fridge and adds a line under his blood pressure pill: oval, pale yellow, the stamp the pharmacist read him, and the month it changed.
He takes the pill. He also writes one more thing: if anything feels different, call Dr. Okafor.
The move to keep
A real failure deserves to be taken seriously. Ask which factory, which batch, and whether it was yours, before you let it stand for everything with the same name. What’s amazing in this situation is that there wasn’t an impossibly high bar for evidence to meet for Ray to change his mind. He wasn’t being cynical. He truly was being a healthy skeptic. He got evidence from a pharmacist, and it changed his mind.
What's the oldest pill bottle in your cabinet? Hold that thought. We'll come back to it at the end.
This is Small Doses, No. 5 of 12. One viral health claim a week, taken apart a small dose at a time.
In the news
On October 11, 2026, HBO's Last Week Tonight with John Oliver spent its main story on generic drugs: contaminated eye drops, a children's cancer drug that ran short, and overseas factories that do better on inspections when they know inspectors are coming. Those stories are real, and they're about the factory. First, the other half: the test a generic has to pass. Here are five things you'll hear, checked the skeptic's way.
1. "Generics are weaker"
What people say: "Generics are cheap copies. They don't work as well."
What's partly true: a generic isn't an identical twin.
The FDA requires a generic to have the same active ingredient, strength and form as the brand, taken the same way. What can differ is everything around the medicine: fillers, dyes, coatings, shape and color.
The skeptic's question: what test did it have to pass?
A bioequivalence study: does the copy land in the body the same way as the original? Volunteers take both, and their blood is checked on a schedule. If the results don't match within a tight window, the generic isn't approved.
Is a generic ever not as good? Rarely, and the system has caught it. In 2012, the FDA found that a generic extended release antidepressant didn't match the brand, and later pulled its approval. In 2014, it downgraded two generic versions of an extended release ADHD medicine so pharmacies couldn't swap them in automatically.
Both were slow release pills, which are harder to copy, and both were caught after reaching shelves. That's not proof the system is perfect. It is evidence that it can catch its own mistakes, in public.
2. "They can have 20% less medicine"
What people say: "The rules let a generic be 20% weaker."
What's partly true: 80 and 125 are real numbers in the rule.
The skeptic's question: what does the number actually measure?
The 80 to 125 range is a window, and the study's whole result, margin of error included, has to fit inside it. A generic that was truly 20% weaker would fail.
The whole bar has to fit inside the window, not just touch it.
The real numbers: when FDA scientists reviewed 2,070 of these studies, generics differed from the brand by about 3.5 to 4.5% on average in how much medicine reached the blood. In nearly 98% of them, the difference was under 10%.
3. "My pill looks different, so something's wrong"
What people say: "They changed my pill. Something must be off."
What's partly true: something did change.
The skeptic's question: who makes my pill now?
So when a refill suddenly looks different, the most likely reason is that your pharmacy switched suppliers, and each maker uses its own shapes and colors. Ask the pharmacist who makes it now. The letters and numbers stamped on the pill, called the imprint, tell them exactly which product you have.
4. "Generics come from dirty factories. Brand names don't."
What people say: "Generics are made overseas in plants nobody checks."
What's partly true: real factories have failed, and people got hurt.
In 2023, over the counter artificial tears made at a plant in India were linked to an outbreak of a drug resistant infection. By May 2023, the CDC counted 81 patients in 18 states. Four died, 14 lost vision, and four had an eye removed.
Eye drops sit everywhere, even by the register. The 2023 outbreak traced back to one factory, not to generics as an idea.
The skeptic's question: which factory, which batch?
That outbreak was about one factory, not about generics as an idea. The FDA holds every factory, brand or generic, anywhere in the world, to the same manufacturing rules, and checks them with inspections. In May 2025, it said it would send more surprise inspectors to factories overseas. This is a reason to ensure proper funding and resource allocation to the FDA and how public health and legislation can directly impact you when you buy eye drops at the checkout lane at the grocery store.
Brand name medicines get recalled too. In 2021, the maker of a brand name smoking cessation pill recalled it over an impurity, and by September the recall covered every lot. Quality is a factory question, not a generic question.
It goes the other way too. In July 2018, the FDA announced a recall of several generic blood pressure medicines containing valsartan after a likely cancer causing impurity was found. Patients were told to keep taking them until their pharmacist or doctor could replace them.
And a compounded drug is not an FDA approved generic. The FDA doesn't review compounded drugs before they're sold, and the October report that found black mold at two plants in China was about ingredients for compounded weight loss drugs.
5. "If it were the same, it wouldn't be so cheap"
What people say: "You get what you pay for."
What's partly true: cheap has a cost, and it shows up as shortages.
Generic margins can get so thin that companies stop making a drug. In 2019, one of only two makers of vincristine, a chemotherapy drug used in childhood cancer, stopped making it as a business decision.
When a cheap drug stops being worth making, the gap shows up on a shelf like this.
The skeptic's question: what does the low price actually pay for?
A generic is cheap because its maker doesn't repeat the big trials that proved the original works, and because several companies compete to make it. Generics fill about 9 in 10 US prescriptions, according to the generic industry's trade group. The low price says nothing bad about the medicine.
Where the system falls short
None of this is a defense of the drug industry. Some of it deserves the frustration people feel.
Nobody tells you. Your pill can change makers between refills, and you find out by opening the bottle. Ray's question is a fair one.
Factories fail on both sides. Inspections catch a lot. They don't catch everything.
And one more belongs to the brand side: legal moves that keep a generic off the shelf longer, which helps keep some brand drugs expensive for years. If 9 in 10 prescriptions are cheap generics, why does the pharmacy counter still hurt? That question deserves its own receipts.
How a generic gets approved
This is the part of the story I've spent my career next to. I’m Justin Yamashita, a senior project manager in oncology clinical research. In the open: I work in clinical trials, so I have a professional stake in this industry. No company paid for, saw or approved this issue.
The room where they measure the copy
Picture a clinical research unit at 7:58 in the morning. A row of recliners, a wall clock, a printed timetable of blood draw times. Everyone in the chairs is healthy, and almost nobody looks busy. They're reading, scrolling, one is asleep.
7:58 in the morning. Healthy volunteers, a wall clock, and a timetable of blood draws.
Each takes a single pill: half get the brand, half the generic. After a washout period, long enough for the first pill to leave the body, they come back and switch. Each person is their own comparison.
Then it's blood draws, on a schedule, all day: how fast the medicine shows up, how high it goes, how much gets in. Those numbers are what FDA compares against the window in claim 2.
Why it reaches your cabinet
Here's what most people never think about. About 9 in 10 prescriptions in this country are filled with generics, so a study like this one, in a room you'll never see, sits behind most of the pills in your cabinet. The pill on your counter can change makers between refills, and nobody calls to tell you. And when a generic gets so cheap that nobody wants to make it, the shortage doesn't land on a factory. It lands on a hospital trying to treat a child's cancer.
The study happens in a room you'll never see. The result ends up in here.
It reaches past the pharmacy counter, too. Many store-brand allergy and heartburn pills are approved generics. Store-brand loratadine, the copy of Claritin, had to pass this same blood level test before it hit the shelf. Some older staples, like acetaminophen, follow a different FDA rulebook instead, one that sets the ingredient and the dose rather than testing each product against a brand.
Many store-brand allergy and heartburn pills passed the same test as the brand on the next shelf.
The people in those recliners at 7:58 are a big part of why your copay, and that store-brand box, cost what they do.
Same recipe, different kitchen
Think of a generic as a recipe cooked in a different kitchen. The bioequivalence study is a taste test against the original dish, with lab equipment instead of a tongue. If the copy doesn't match, it doesn't get approved.
Approval tests the recipe once. Inspections check the kitchen for as long as it keeps cooking. That second job is where the stories from the TV segment live.
Where the analogy bends: inhalers, creams and some injections are harder to copy, and FDA asks for more evidence for those.
The Skeptic's Toolkit
Every question here comes from the full toolkit.
The full Skeptic's Toolkit.
Copy this
For the next time someone says "my pill changed, so something's wrong":
"A generic has to show it gets into your blood the same way as the brand, usually within a few percent. The real risk is in how carefully each batch gets made, and that applies to brand name drugs too. If your pill looks different, ask the pharmacist who makes it now. Don't stop taking it on your own."
Save it. Send it the next time it comes up.
What this means for you
Don't stop or switch a medicine on your own. If something about a refill worries you, call your pharmacist or prescriber first.
Ask who makes it. Your pharmacist can tell you the manufacturer and read you the imprint, the letters and numbers stamped on the pill.
Write it down. Our free Medication and Supplement Log has room for every medicine you take, plus the maker and what the pill looks like.
Want to dig? ProPublica's Rx Inspector and FDA's Orange Book are free to search. A bad inspection report doesn't mean your pills are bad, so bring what you find to your pharmacist.
Mention allergies. Fillers and dyes differ between makers. If you react to something like lactose or a dye, tell the pharmacist.
For a few medicines, staying on one maker matters more. For thyroid medicine, the blood thinner warfarin and some seizure medicines, ask to stay on the same maker, and tell your doctor if it changes.
Report it. If a medicine stops working the way it used to, tell your prescriber. You can also report it to FDA through MedWatch.
The Wall of Sams
Remember the oldest pill bottle in your cabinet? Go look at the label. Does it say who made the medicine inside? Most people have never checked.
Then tell us: has a refill ever come back looking different? What did you do, and did anyone explain why? Reply to this email or leave a comment on the newsletter. With permission, a few of your stories may show up in a future issue.
Seen a health claim that's bugging you? Send it to us. It takes a minute, and the ones that come up most become a Wednesday issue.
Send this to one person
Know someone whose refill just looked different? Pick a line and use your own link below. It counts toward your Series 1 card.
To a parent: "This finally explained whether the store brand is really the same medicine. Short, and it doesn't preach."
To an older relative: "Has your pill ever changed color on you? This explains why, and what to ask."
The Bridge
The study that approved the generic in your cabinet was a clinical trial. Healthy volunteers, in a room like the one above, gave their time and blood so you could pay less.
Some of those studies are looking for healthy volunteers right now. You can browse them on our registries page. Looking commits you to nothing.
The bridge from drug discovery to medicine in your medicine cabinet takes decades, it takes volunteers, and it takes awareness. The bridge can be shortened by increasing awareness about the need for volunteers and funding. This is where you can help!
Every claim sits somewhere on the bridge. The brand built the crossing. The generic proves it lands in the same place.
Where generics sit: We know. The original crossed the whole bridge in large trials. The generic crosses one short span of its own to prove it lands in the same place.
New here? What Root to Rx Is
Free, every week, no sponsor.
Wednesday, Plain Talk. Each issue now opens in The Root Room, where you watch a real health claim try to work on somebody. Then we take it apart in plain language, with the receipts at the foot of it.
Tuesday, The Open Site File. What the job actually looks like from inside a clinical trial site. If you have ever thought about moving into clinical research coordinating, start there.
Sunday, The Roots, on LinkedIn and Substack. A weekly letter for the people who get asked, the ones whose family treats them as the medical desk.
The Receipts
1. Last Week Tonight with John Oliver. "Generic Drugs." HBO, October 11, 2026.
2. AV Club. John Oliver takes a close look at generic drugs, says viewers should, too. October 12, 2026.
3. Bloomberg. Report on FDA inspections of two Chinese plants making ingredients for compounded semaglutide and tirzepatide. October 15, 2026.
5. FDA. Statistical Approaches to Establishing Bioequivalence. Final guidance, May 2026 (replaces the 2001 guidance).
6. Davit BM, et al. Comparing Generic and Innovator Drugs: A Review of 12 Years of Bioequivalence Data from the United States Food and Drug Administration. Ann Pharmacother. 2009;43(10):1583-97.
7. CDC. Outbreak of Extensively Drug-resistant Pseudomonas aeruginosa Associated with Artificial Tears. Update of May 15, 2023.
8. FDA. FDA Announces Expanded Use of Unannounced Inspections at Foreign Manufacturing Facilities. May 6, 2025.
9. BioSpace. Pfizer Looks to Fill Void for Chemo Drug After Teva Discontinues Its Generic Version. October 16, 2019.
10. Association for Accessible Medicines. 2026 U.S. Generic and Biosimilar Medicines Savings Report.
11. FDA. FDA Updates and Press Announcements on Nitrosamine in Varenicline (Chantix). July to September 2021.
13. ProPublica. Rx Inspector. Launched December 18, 2025.
14. RAPS. FDA formally withdraws approval of Budeprion XL 300 mg (bupropion extended release). March 15, 2013.
15. RAPS. FDA says it discovered problems with generic versions of Concerta (methylphenidate extended release), reclassifies them from AB to BX. November 2014.
16. FDA. FDA Updates and Press Announcements on Angiotensin II Receptor Blocker (ARB) Recalls (Valsartan, Losartan, and Irbesartan). July 13 and 18, 2018.
19. FDA. Over-the-Counter List of Off-Patent, Off-Exclusivity Drugs without an Approved Generic. Methodology note: OTC monograph products are not approved through the NDA or ANDA process.
21. BioSpace (Business Wire). Andrx Corporation Receives FDA Approval for Loratadine Orally Disintegrating Tablets (approved generic, bioequivalent to Claritin RediTabs, sold as a store brand through Perrigo). November 4, 2003.
22. MedShadow Foundation. What's Really Inside Your OTC Drugs? (monograph products such as acetaminophen have no bioequivalence data in the Orange Book).
23. Root to Rx. Plain Talk 024: Who Checks the Room Your Medicine Is Made In?
Try it yourself: see if you'd have caught this week's costume on your own.
The Skeptic Type quiz sorts you into your pattern in about two minutes.
Got Skepticism? runs any claim through the questions in the Skeptic’s Toolkit, including the one from this issue: which factory, which batch?
Stay in the Room shows you how to disagree without a fight so that you can talk to people about these difficult topics.
The quiz and both games play in your browser at Open Label Media, and I would love to see your results on social.
Work in clinical research, or want to? The Open Site File comes out every Tuesday. Get it by email:
Between issues, the free tools live on the site. The Field Guide has printable patient logs and the full Skeptic's Toolkit. If you or someone you love is looking for a trial, there's a walkthrough for finding one near you. And if you've ever wondered why clinical research has the rules it does, Version History tells that story. The tees and mugs that help support the work are in the shop.
For educational purposes only. Nothing in this newsletter is medical advice. Talk to your doctor before making any health decision.
You are receiving this because you subscribed at roottorx.com.
Disclosure: Root to Rx is published independently by Open Label Media LLC. Views expressed are personal views of Justin Yamashita and do not represent his employer or any affiliated organization. No employer resources or proprietary information are used. Every claim is sourced from publicly available materials.
Root to Rx | 228 Park Ave S, #29976, New York, New York 10003, United States
